Neos Therapeutics (NEOS) Earning Very Positive News Coverage, Report Shows

News articles about Neos Therapeutics (NASDAQ:NEOS) have been trending very positive recently, AlphaOne reports. AlphaOne, a unit of Accern, identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neos Therapeutics earned a media sentiment score of 0.56 on AlphaOne’s scale. AlphaOne also assigned news stories about the company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

Insider Buying and Selling by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics (NEOS) opened at 8.65 on Friday. Neos Therapeutics has a 12-month low of $4.85 and a 12-month high of $10.73. The stock’s 50 day moving average price is $7.79 and its 200 day moving average price is $6.81. The stock’s market cap is $195.14 million.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Tuesday, May 9th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.94) by $0.07. The business had revenue of $5.63 million for the quarter. Neos Therapeutics had a negative return on equity of 512.10% and a negative net margin of 719.86%. Analysts forecast that Neos Therapeutics will post ($3.23) EPS for the current fiscal year.

A number of brokerages have recently issued reports on NEOS. Zacks Investment Research upgraded Neos Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a research report on Tuesday. ValuEngine lowered Neos Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 27th. Cowen and Company began coverage on Neos Therapeutics in a research report on Wednesday, April 5th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $15.00 target price on shares of Neos Therapeutics in a research report on Saturday, March 11th.

WARNING: This piece was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply